Background The relative intracoronary flow reserve has been found to be reduced during acute transplant rejection, but the effects of rejection on absolute flows at rest and during hyperemia have not been established previously. This has now become possible through noninvasive quantification of myocardial blood flow with positron emission tomography.
Background The relative intracoronary flow reserve has been found to be reduced during acute transplant rejection, but the effects of rejection on absolute flows at rest and during hyperemia have not been established previously. This has now become possible through noninvasive quantification of myocardial blood flow with positron emission tomography.
Methods and Results Myocardial blood flow (MBF) at rest and during dipyridamole-induced hyperemia was quantified in 10 transplant patients (group A) during an acute, biopsy-proven rejection episode and again after successful immunosuppressive treatment and in 6 transplant patients (group B) without prior rejection episodes. In group A patients, MBF during rejection averaged 1.7±0.3 mL. min'1 g~' at rest and 2.5±0.9 mL* min-1 g-' during hyperemia; after recovery, MBF at rest had declined to 1.2±0.3 mL . -1 g-1 (P<.001) but had increased to 3.9± 1.1 mL*1 . g-1 (P<.001) during hyperemia. Flows after recovery from rejection were similar to those in the group B patients (0.9±0.2 and 3.9±0.7 mL. min' . g-1). Flow reserve in the group A patients was only 1.5±0.5 during rejection but improved to 3.4±0.9 at recovery (P<.001) and thus remained lower than in the control patients (4.5±0. 7 vated during rejection (40±11 mm Hg * mL-* min' * g-1); after recovery, it no longer differed from that in the group B patients (26±11 versus 22±4 mmHg mL-1 min-' g '). MBF during rejection was increased relative to cardiac work, as demonstrated by significantly higher ratios of blood flow to rate-pressure product than those at recovery and in the control patients.
Conclusions A decrease in hyperemic and an increase in resting myocardial blood flow, in excess to cardiac work, account for the previously reported reduction in coronary flow reserve. Because both alterations improve with antirejection treatment, they may reflect reversible alterations, presumably of endothelial function, local coagulation, and edema. The compromise in flow reserve and hyperemic flows may contribute to acute and chronic injury from rejection and thus provides a rationale for exercise restriction during rejection. The results further suggest a potential role for serial noninvasive flow measurements to guide immunosuppressive therapy. (Circulation. 1994;90:204-212.)
Key Words * cardiac allograft rejection * myocardial blood flow * positron emission tomography * myocardial flow reserve 24 hours after transplantation and decreased markedly approximately 24 hours before death. Peak reactive hyperemia flows were normal early after transplantation but declined progressively. The decline in peak reactive hyperemic flows preceded the fall in resting flow by several days. Terminally, reactive hyperemia was minimal or absent.
Recently, Nitenberg et a14 demonstrated with the coronary sinus thermodilution technique an impaired coronary vasodilator response to dipyridamole in humans with histological evidence of cardiac allograft rejection. Subsequent studies with intracoronary flow velocity probes confirmed these findings and again demonstrated a reduced ratio of peak to resting coronary flow velocity during acute rejection.5 Recovery from acute rejection was followed by normalization of the coronary flow reserve.
However, both coronary sinus thermodilution and intracoronary Doppler flow velocity measurements are invasive, do not yield values of myocardial blood flow in absolute terms, and, in the case of intracoronary flow probes, measure only flow velocities of one coronary artery. It remains unknown whether the observed reduction in flow reserve is due to an increase in blood Diast  Group A patients   1  86  124  94  94  120  91  91  112  87  95  121  81  2  76  132  82  79  124  74  80  147  100  82  137  89  3  74  116  82  78  114  76  88  132  84 The patients were divided into two groups: group A consisted of 10 patients who were studied first within 24 hours of a myocardial biopsy (harvest of three to four tissue specimens) that demonstrated acute moderate rejection but before initiation of antirejection therapy (study 1, 6 .9+7.5 weeks after transplantation) and again 15 The 900-second images, recorded at the end of the acquisition sequence, were evaluated for segmental reductions in N-13 ammonia uptake both at rest and during dipyridamole. Additionally, after reorientation of the images into short-axis views and generation of polar maps, the relative tracer distribution in the 10 group A patients was compared against a database of normal subjects as established previously in our laboratory.9 This was done to examine whether the acute rejection affected myocardial blood flow at rest and during hyperemia homogeneously.
Cakulation of Myocardial Blood Flow
The serially acquired transaxial images were transferred to a Macintosh II computer and reoriented into left ventricular short-axis views as described previously.10 Three short-axis cross sections, representing the base, midportion, and apex of the left ventricle, were used for quantitative analysis. The left ventricular myocardium on the short-axis cross sections was outlined using a semiautomatic computer program10 and divided into six sectors. The outline and sectorial regions of interest were copied to all serial images, and average tissue activity concentrations for each region in counts/mm2 were calculated.
Myocardial activity thickness of the left ventricle was determined by deconvolution of radioisotope activity profile from the center of the left ventricle to outside the ventricle."",12
Recovery coefficients based on myocardial activity thickness and cardiac wall motion were used to adjust the measured tissue activity concentrations for corrections of partial volume. A small blood pool region of interest (5 to 79 mm2 in size) corresponding to the left ventricular cavity was assigned manually to the most basal short-axis cross section on each serial image, and an arterial input function was generated. Interstudy and intrastudy differences accounted for the range in the size of the blood pool region of interest. The size was tailored to the ventricular size but also to the relative activity concentration in the blood pool. For Table 1 lists the individual heart rates and blood pressures in the two patient groups; Table 2 summarizes hemodynamic measurements. In the group A patients at the time of rejection (study 1), only the heart rate increased significantly from rest to dipyridamole-induced hyperemia (P<.001), whereas blood pressures remained unchanged. In the same patients, no significant changes in hemodynamic parameters at rest between the rejection and the recovery studies occurred except for a modest but statistically significant increase in the rate-pressure product (P<.025). Dipyridamole infusion at the time of the recovery study (study 2) remained without a statistically significant effect on hemodynamic parameters except for a modest decrease (5.4±6.0%) in systolic blood pressure (P<.05).
The hemodynamic parameters in the group A patients at both study times did not differ significantly from those in the group B patients. Dipyridamole infusion in the group B patients resulted in modest but statistically significant increases in heart rate and the rate-pressure product, whereas blood pressures remained unchanged. No patients suffered from major adverse reactions to dipyridamole including chest pain, heart block, or acute asthmatic attacks. Minor adverse events like "feeling flushed" or diaphoresis occurred in 2 subjects during study 1 and in 4 patients during study 2 in the group A patients and in 3 of the 6 group B patients.
Myocardial Blood Flow
Visual inspection of both the transaxial and the short-axis cross-sectional images revealed homogeneously distributed N-13 activity throughout the left ventricular myocardium in all studies both at rest and during dipyridamole-induced hyperemia. The homogeneity of blood flow was further supported by the coefficient of variation, which was similar in both the rest and hyperemia studies at the time of the acute rejection period and after recovery in the group A patients as well as in the group B patients (Table 2) . Furthermore, the coefficients of variation obtained in this study were similar to those observed previously in a group of 20 normal volunteers. '5 Comparison of the polar maps to a database of normal in the 10 group A patients did not reveal flow defects either at rest or during dipyridamoleinduced hyperemia.
Myocardial blood flow in the group B patients did not differ significantly from that reported previously for normal volunteers from our laboratory.15 Thus, resting blood flow, hyperemic blood flow induced by intravenous dipyridamole, and flow reserve were similar in transplant recipients at 7.7±4.8 weeks without prior episodes of rejection and normal volunteers. 15 Blood flow at rest in the 10 group A patients at the time of the acute rejection averaged 1.7±0.2 mL* min g-1 (Tables 3 and 4 ). This was significantly higher than the blood flows at rest after the patients had recovered from the acute rejection episode (1.2±0.3 mL* min' * g-1, P<.0005). At that time, blood flows at rest no longer differed from those in the group B patients (0.9+0.2 mL* min-l. g-1, NS), whereas they had been significantly higher during rejection (P<.001). Fig 1 depicts the individual myocardial blood flows at rest of group A patients during acute rejection (study 1) and after recovery (study 2) and the group B patients. The increase in resting blood flow during acute rejection was still present even when cardiac workload as estimated by the heart rate-systolic blood pressure product was taken into account (Fig 2) . The ratio of resting blood flow to the rate-pressure product decreased in group A patients between acute rejection and after recovery (1.6+0.2x 10-4 to 1.1±0.3x 10-4, P<.005). However, as listed in Table 4 , this ratio was not significantly different between recovery and group B patients (1.0±0.4x10-4, P=NS).
In contrast, hyperemic blood flows were markedly depressed during the acute rejection episode. They averaged only 2.5±0.9 mL* min-lj* g`and thus were significantly lower than in the group B patients without rejection (3.9±0.6 mL -min-* g-', P<.05). Successful treatment of the rejection episode resulted in a marked increase in the hyperemic flows to 3.9±1.1 mL. min-1' g-', which no longer differed from the control patients in group B. Compared with the group B patients, the myocardial blood flow reserve as depicted in Fig 3 was markedly reduced in the group A patients at the time of the rejection. The decline in rest and the increase in hyperemic blood flows after successful treatment of the rejection episode resulted in a marked increase in the myocardial flow reserve (3.4±0.9, P<.001). However, this value was still lower than that in the group B patients without any prior rejection episode (4.5 ±0.7, P<.05). Concordant with these changes was a significant decline in the minimal coronary resistance during dipyridamole-induced vasodilation in the group A patients (P<.05, see Table 4 ). Furthermore, minimal coronary resistance after recovery in the group A patients no longer differed significantly from that in the control patients (25.8±11.3 versus 22.2±3.6 mm Hg* mL-1* g. min-1).
Discussion
The observation of a reduced myocardial flow reserve during acute moderate rejection is consistent with earlier findings of a reduced coronary flow velocity reserve as measured with intracoronary Doppler flow velocity probes. On the other hand, the current study demonstrates that this reduced flow velocity ratio is due to lower, pharmacologically induced hyperemic blood flows as well as to an increase in resting blood flow, which was in excess of the rate-pressure product and thus of cardiac work.
The increase in resting blood flow occurred despite similar heart rates and blood pressures during acute rejection and after recovery and despite a modest but statistically significant increase in cardiac work. On the other hand, pharmacological vasodilation with intravenous dipyridamole produced significantly lower hyperemic flows in patients during rejection than after recovery as well as in patients without prior allograft rejection. This was despite similar heart rates and blood pressures during recovery. Thus, myocardial flow reserve was significantly depressed during acute rejection but improved after recovery. However, flow reserve as the ratio of hyperemic to rest blood flows was still diminished after recovery from the acute rejection period when compared with the myocardial flow reserve in cardiac transplant patients without prior episodes of acute rejection. .
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Dip indicates hyperemia study after intravenous dipyridamole.
The findings obtained noninvasively in this study with positron emission tomography are consistent with those reported previously through invasive techniques using intracoronary Doppler flow velocity probes and intracoronary injection of papaverine or adenosine. Using the peak to baseline flow velocity ratios as an index of coronary flow reserve, these studies reported normal flow reserves in nonrejecting transplants,5'6-18 a significant reduction during acute transplant rejection, and normalization after successful rejection therapy.5 However, intracoronary flow velocity probes yield only ratios of coronary flows. Furthermore, these probes provide information on regional flows only but not on total myocardial blood flow. Accordingly, these measurements do not yield absolute coronary or myocardial blood flow.
Earlier investigations have indeed measured myocardial blood flow and flow reserve in cardiac transplants with positron emission tomography and N-13 ammonia or 0-15 water as tracers of myocardial blood flow.19-2' Most of these studies in nonrejecting allografts revealed normal hyperemic but increased resting blood flows so that myocardial flow reserve was lower than in normal volunteers.20'2 The increase in resting blood flow had been attributed to an increase in cardiac work at rest, as evidenced by increased rate-pressure product.'9-21 Similar to these earlier observations, blood flow and the ratepressure product at rest during rejection were higher than in normal volunteers studied previously in our laboratory.15 Furthermore, resting blood flows during rejection correlated directly with the rate-pressure product. With recovery from rejection, the rate-pressure product at rest slightly but significantly increased, but blood flows declined. Although individual blood flows varied considerably and some values were higher than their respective rate-pressure products, average blood flow and rate-pressure products after recovery no longer differed significantly from those in the nonrejecting control group, although they tended to be higher. The comparable ratios of blood flow to rate-pressure product indicated a similar although more variable relation between blood flow and cardiac work in both patient groups. Conversely, the higher blood flow to rate-pressure product ratio during rejection, together with the divergent changes in flow and cardiac work from rejection to recovery, imply that resting blood flow during the rejection was increased relative to cardiac work. The current findings do not offer a mechanistic explanation for this observation but suggest that the disproportionate increase in resting blood flow may reflect "inflammation-related hyperemia," mediated through endothelium-dependent and direct vascular smooth muscle effects of cytokines as an integral part of the rejection process. Thus, the normal local regulation of coronary blood flow may be disturbed during rejection. are not explained by differences in heart rate or blood pressures.
Myocardial blood flow in this study was quantified noninvasively with intravenous N-13 ammonia and dynamic positron emission tomography, using a previously established tracer compartment model validated in animal experiments10,2627 and previously used in normal volunteers, patients with coronary artery disease, and patients with cardiac transplants.3,1519,28 Time-activity curves for arterial blood and myocardial activity concentrations were derived from reoriented short-axis rather than the originally acquired transaxial cross sections. Animal experimental studies have demonstrated the superiority of this approach for quantitative measurements of myocardial blood flow.10 Also, the approach yields reproducible estimates of blood flow. Repeat measurements in our laboratory of baseline and hyperemic blood flows on different days in normal volunteers demonstrated an average random variability of only about 10% (unpublished data). The relatively small and random variability in these reproducibility studies is markedly different from the directional changes (about 50%) in rest and hyperemic blood flows in the group A patients.
The measurement approach included a correction for partial volume effects based on activity thickness measurements directly from the short-axis images of the left ventricular myocardium. This approach has been validated in human myocardium against wall thickness measurements by gated magnetic resonance imaging and echocardiography.12 In addition to the animal experimental studies, the validity of the flow measurements approach appears to be supported further by the nearly identical values of flow reserves obtained independently by intracoronary flow velocity probes, as reported by others. 5 
